1. Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

2. Guideline Recommendations

3. Approximate Dose Equivalency of Statin LDL-C Efficacy

4. NEPTUNE II Trial

5. Residual CV Risk

6. Intensive Statin Therapy: Residual CV Risk

7. Combination Therapy

8. Statin + Fibrates

10. VA-HIT: Gemfibrozil Prevents Secondary CVD Events

12. ACCORD Lipid: Hazard Ratios for the Primary Outcome

13. Comparison of ACCORD Subgroup Results With Those From Prior Fibrate Studies

14. Statin + Niacin

16. AIM-HIGH: End Point at 36-month Follow-Up

17. HPS2-THRIVE: Effects of Niacin/Laropiprant on Lipids

18. HPS2-THRIVE: Major Vascular Events

19. Statin + Ezetimibe

20. Statin and Ezetimibe Trials

21. Statin and Ezetimibe

22. ENHANCE Simvastatin/Ezetimibe in Familial Hypercholesterolemia

23. ENHANCE Simvastatin/Ezetimibe in High Cholesterol Absorbers and Synthesizers

24. ENHANCE Change in Intima Media Thickness of Carotid Artery

25. EZ-Switch Study: Ezetimibe Added to Atorvastatin vs Atorvastatin Up-Titration or Switching to Rosuvastatin

26. LDL-C: Percentage Change From Baseline at End of Phase 1/2

27. ARBITER 6-HALTS Trial

29. Statin + Bile Acid Sequestrants

31. Comparison of CETP Inhibitors

32. DAL-OUTCOMES: 3 Years

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)